NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMNIPRED (prednisolone acetate) is a corticosteroid ophthalmic suspension approved in 1973 for treating ocular inflammation and allergic conditions. It works by inhibiting inflammatory mediators through induction of lipocortins, which block prostaglandin and leukotriene biosynthesis. The drug is indicated for seasonal allergic conjunctivitis, uveitis, corneal edema, and post-operative inflammation.
LOE Approaching
As an approaching loss-of-exclusivity product, the brand team is likely in maintenance-to-transition mode with reduced commercial investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Started May 2010
90 enrolled
Intraocular Inflammation
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
Started Mar 2009
52 enrolled
CataractsCorneal EdemaRetinal Structural Change, Deposit and Degeneration+1 more
A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
Started Jul 2005
132 enrolled
Eye InfectionsPostoperative Complications
Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee
Started Oct 2004
Osteoarthritis, Knee
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Started Aug 2004
62 enrolled
Cataract Surgery
Worked on OMNIPRED at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.